Related Experiment Video
Updated: Aug 22, 2025

Vaccinia Reporter Viruses for Quantifying Viral Function at All Stages of Gene Expression
Published on: May 15, 2014
New Perspectives on Antimicrobial Agents: Tecovirimat for Treatment of Human Monkeypox Virus
Clare E DeLaurentis1, Jennifer Kiser2, Jason Zucker1
1Division of Infectious Diseases, Columbia University Medical Center, New York, New York, USA.
Abstract:
Tecovirimat is an antiviral drug initially developed against variola virus (VARV) to treat smallpox infection. Due to its mechanism of action, it has activity against the family of orthopoxviruses, including vaccinia and the human monkeypox virus (HMPXV). Efficacy studies have thus far been limited to animal models, with human safety trials showing no serious adverse events. Currently approved by the FDA only for the treatment of smallpox, tecovirimat shows promise for the treatment of HMPXV. Tecovirimat has been prescribed via an expanded access for an investigational new drug protocol during the 2022 outbreak. This review will examine the literature surrounding tecovirimat's mechanism of action, pharmacokinetics, safety, efficacy, and potential for resistance.
More Related Videos
Related Concept Videos
Antimicrobial Effectiveness
Subviral Agents
Retroviruses
Biological Methods for Microbial Control

